Sterically stabilized liposomes in cancer therapy and gene delivery

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 2, 1999, Pages 177-185

  Lasic, D D ^a   Vallner, J J ^b   Working, P K ^b  

^a Liposome Consultations   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DERIVATIVE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DRUG CARRIER; LIPOSOME; MACROGOL; NUCLEIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; GASTROINTESTINAL SYMPTOM; GENE TARGETING; HUMAN; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOXORUBICIN; GENE THERAPY; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 0033041992     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lasic DD, Martin FJ (Eds): In: Stealth Liposomes. CRC Press, Boca Raton (1995).
2. Woodle MC, Storm G (Eds): In: Long circulating liposomes. Springer, Berlin (1997).
3. Lasic DD, Papahadjopoulos D: Liposomes Revisited. Science (1995) 267:1275-1276.
4. Lasic DD, Papahadjopoulos D (Eds): In: Medical Applications of Liposomes. Elsevier Amsterdam, New York, Tokyo (1998). An up-to-date review on the whole area of medical applications of liposomes. In the Current Opinion series journals, references older than 3 years are not usually cited. In this review we refer to cited and uncited contributions in this article for review of the older literature.
5. Lasic DD: Doxorubicin in sterically stabilized liposomes. Nature (1996) 380:561-562. A brief overview of the DOXIL formulation, its physicochemical properties and antitumor activity in colon C26 and mammary MC2B tumor models.
6. Lasic DD, Needham D: Stealth liposomes - a prototypical biomaterial. Chem Rev (1995) 95:2601-2623. A comprehensive review on physicochemical properties of sterically stabilized liposomes. Mechanical properties of liposome bilayers are reviewed and values of stretching elastic moduli are tabulated.
7. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB: Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochem Biophys Acta (1997) 1331:187-211. Reviews various remote loading techniques of liposomes, from pH gradient to ammonium sulfate gradient methods.
8. Working P, Newman M, Vaage J, Mayhew E, Lasic DD: Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in stealth liposomes. J Liposome Res (1993) 4:667-682. Preclinical data on epirubicin and doxorubicin in stealth liposomes in colon C26, primary and metastatic mammary M2CB carcinoma and human lung tumor xenografts are reviewed. (Original data in Proc Natl Aca Sci USA (1991) 88:11460-11464; Int J Cancer (1992) 51:302-309 and 51:942-948; and Cancer Res (1992) 52:6774-6781 and (1993) 53:3964-3968).
9. Vaage J, Uster PS, Working P: Therapy of human carcinoma xenografts with DOXIL: efficiency and safety.. In: Long circulating liposomes. Woodle MC, Storm G (Eds), Springer, Berlin(1997):61-72.
10. Working P: Preclinical studies of lipid complexed and liposomal drugs. AMPHOTEC®, DOXIL® and SPI-077 In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds), Elsevier Amsterdam, New York, Tokyo(1998):605-624. Comprehensive presentation of the three products.
11. Martin F: Clinical pharmacology and antitumor efficacy of Doxil (Pegylated liposomal doxorubicin). In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds): Elsevier Amsterdam, New York, Tokyo (1998):635-688. Detailed review of DOXIL use in humans
12. Ceh B, Winterhalter M, Frederik P, Vallner JJ, Lasic DD: Stealth liposomes: from theory to product. Adv Drug Del Rev (1997) 24:165-177. Reviews basic physics and chemistry of liposome stability and drug encapsulation and describes the manufacturing procedure.
13. Gabizon A: Clinical studies of liposomes as carriers of chemotherapeutic agents: synopsis and perspective. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds): Elsevier Amsterdam, New York, Tokyo (1998):625-634 Review of doxorubicin studies in humans since early 1980s.
14. Uziely B, Jeffers S, Isacson R, Kutsch K, Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncol (1995) 13:1777-1785.
15. Muggia F, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Mudersprach L, Garcia A, Burnett A, Greco A, Morrow P, Paradiso L, Liang L: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 15:987-993.
16. Goebel FD, Goldstein D, Goos M, Jablanowski H, Stewart JS: Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer (1997) 73:989-994.
17. Northfelt D: DOXIL in the treatment of AIDS related Kaposi sarcoma. In: Long circulating liposomes. Woodle MC, Storm G (Eds) Springer, Berlin (1997):126-145.
18. Working PK, Newman MS, Sullivan T, Yarrington J: Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long circulating pegylated liposomes. J Pharmacol Exp Therap (1999) in press.
19. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Annals Oncol (1998) 9:711-716.
20. Newman MS, Colbern GT, Working PK, Engbers CE, Amantea MA: Comparative pharmacokinetics, tissue distribution and therapeutic efficacy of cisplatin encapsulated in long circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol (1999) 43:1-7.
21. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z, Turner N: Comparative toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci (1998) 46:155-165.
22. Allen TM, Hansen BH, Stuart DD: Targetted sterically stabilized liposomal drug delivery. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds), Elsevier Amsterdam, New York, Tokyo (1998):297-324.
23. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Knotts C, Wood WI, Papahadjopoulos D: Development of anti p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA (1995) 92:1327-1331.
24. Kirpotin D, Park JW, Hong K, Yi S, Colbern G, Zheng W, Meyer O, Benz CR, Papahadjopoulos D: Targeting of sterically stabilized liposomes to cancers expressing HER2/neu proto-oncogene. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds); Elsevier, Amsterdam, New York, Tokyo (1998):325-346.
25. Lasic DD, Papahadjopoulos D: Cancer therapy, introduction and general strategies. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds), Elsevier Amsterdam, New York, Tokyo (1998):221-230.
26. Harding JA, Engbers CM, Newman MS, Goldstein N, Zalipsky S: Immunogenicity and pharmacokinetic attributes of PEG grafted immunoliposomes. Biochim Biophys Acta (1997) 1327:181-192.
27. de Menenzes DEL, Pilarski LM, Allen TM: In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res (1998) 58:3320-3330.
28. Lasic DD: In: Liposomes in Gene Delivery. CRC Press, Boca Raton (1997).
29. Papahadjopoulos D, Nicolau C: Liposomes and Gene delivery - a perspective. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds), Elsevier Amsterdam, New York, Tokyo (1998) 4:347-352.
30. Kabanov VA, Felgner PL, Seymour LW (Eds): In: Self-assembling complexes for gene delivery. Wiley and Sons, Chichester (1998).
31. Lasic DD, Barenholz Y (Eds): Nonmedical Applications of Liposomes. In: From Gene Therapy and Ecology to Diagnostics: Vol IV, CRC Press, Boca Raton (1996).
32. Felgner PL: Improvement in cationic liposomes for in vivo gene delivery. Hum Gene Ther (1996) 7: 1791-1793. Brief review of the development in the field.
33. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis G: Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 15:647-652.
34. Uster P, Allen TM, Daniel BE, Mendez CJ, Newman M, Zhu G: Insertion of PEG derivatized lipids into pre-formed liposomes results in the prolongation of blood circulation times. FEBS Lett (1996) 386:243-246.
35. Liu F, Qi H, Huang L, Liu D: Factors controlling the efficiency of cationic lipid mediated transfection in vivo via ivadministration. Gene Ther (1997) 4:517-523.
36. Hong K, Zheng W, Baker A, Papahadjopoulos D: Stabilization of cationic complexes by polyamines and PEG-phospholipid conjugates for efficient in vivo delivery. FEBS Lett (1997) 400:233-237.
37. Huang KSK, Oto E, Jin B, Hassanipour M: Stable polycation condensed DNA-liposome complexes for systemic gene expression in mice. In: Liposome advance, Book of Abstracts. Gregoriadis G, Florence AT (Eds), (1996):32.
38. Eastman SJ, Lukason M, Toussignant J, Murray H, Lane MD, St George J, Akita G, Cherry M, Cheng S, Scheule RK: A concentrated and stable aerosol formulation od cationic lipid:DNA complexes giving high level gene expression in mouse lung. Hum Gene Ther (1997) 8:765-773.
39. Chillon L, Lee JH, Fasbender A, Welsh MJ: Adenovirus complexed witg PEG and cationic lipids is shielded from neutralizing antibodies in vitro. Gene Ther (1998) 5:995-1002.
40. Filion MC, Philips NC: Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cell. Biochim Biophys Acta (1997) 1329:345-356.
41. Wang S, Lee RJ, Causchon G, Gorenstein DG, Low PS: Delivery of antisense oligonucleotides against HEGF receptor into cultured KB cells with liposomes conjugated to folate via PEG. Proc Nat Acad Sci USA (1995) 92:3318-3322.
42. Meyer O, Kirpotin D, Hong K, Sterneberg B, Park JW, Woodle MC. Papahadjopoulos D: Cationic liposomes coated with PEG as carriers for oligonucleotides. J Biol Chem (1998) 273:15621-15627.
43. Reynolds MA, Sandberg JA: Lipid based carriers enhance biodistribution and efficiency of an anti-angiogenic ribozyme in a Lewis lung carcinoma model. (1999) in preparation.
44. Hagen TLM, van der Veen AH, Eggermont AMM: Long circulating liposome-encapsulated tumor necrosis factor in the treatment of solid tumors. In: Long circulating liposomes. Woodle MC, Storm G (Eds), Springer, Berlin (1997):51-60.
45. Lasic DD: Novel applications of liposomes. Trends Biotechnol (1998) 16:307-321.